Core Insights - Plus Therapeutics, Inc. is advancing its commercial readiness and diagnostic capabilities through the launch of its subsidiary, CNSide Diagnostic LLC, focusing on a laboratory-developed test for cerebrospinal fluid tumor cell enumeration [1][2][3] Commercial Developments - The company has expanded its manufacturing footprint and made significant progress in commercial readiness, including the appointment of key leadership roles to drive the CNSide diagnostic business [2][3] - CNSide has signed a national policy agreement with UnitedHealthcare, providing coverage for over 51 million people in the U.S., marking a significant step in expanding payor coverage [3][4] Leadership Appointments - Russ Havranek has been promoted to Executive Vice President, Commercial and Corporate Strategy, while Daniel Ortega has been appointed Vice President, Development and Technical Operations, both expected to play crucial roles in the company's growth [2][3][4] - Havranek brings over 28 years of experience in developing and commercializing diagnostic and therapeutic products, while Ortega has nearly 20 years of experience in the pharmaceutical industry [4][7] Manufacturing and Operations - CNSide has secured a new state-of-the-art laboratory in Houston, which will support current and future commercial production needs and enhance collaboration opportunities [6][7] - The new facility is strategically located within the Texas Medical Center, the largest medical center globally, which will facilitate scientific advancement and clinical development [7][11] Product and Service Focus - CNSide Diagnostics develops proprietary laboratory-developed tests aimed at identifying tumor cells that have metastasized to the central nervous system, particularly for patients with carcinomas and melanomas [8] - The CNSide CSF Assay Platform allows for quantitative analysis of cerebrospinal fluid, improving patient management for those with leptomeningeal metastases [8][9]